Mechanistic/mammalian target of rapamycin: Recent pathological aspects and inhibitors
- Mechanistic/mammalian target of rapamycin: Recent pathological aspects and inhibitors
- 오창현; 사미르; 엘가말; 다리라; 아쉬라프; 모하메드
- anticancer; kinase inhibitors; mTOR; PI3K; aging
- Issue Date
- Medicinal research reviews
- VOL 39, NO 2-664
- The mechanistic/mammalian target of rapamycin (mTOR), also known as the mechanistic target of rapamycin, regulates many normal cell processes such as transcription, cell growth, and autophagy. Overstimulation of mTOR by its ligands, amino acids, sugars, and/or growth factors leads to physiological disorders, including cancer and neurodegenerative diseases. In this study, we reviewed the recent advances regarding the mechanism that involves mTOR in
cancer, aging, and neurodegenerative diseases. The chemical and biological properties of recently reported small molecules that function as mTOR kinase inhibitors, including adenosine triphosphate‐ competitive inhibitors and dual mTOR/PI3K inhibitors, have also been reviewed. We focused on the reports published in the literature from 2012 to 2017.
- Appears in Collections:
- KIST Publication > ETC
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.